Showing 6191-6200 of 7740 results for "".
- PatientFi Expands Co-marketing Agreement with Allerganhttps://practicaldermatology.com/news/patientfi-expands-co-marketing-agreement-with-allergan/2461148/PatientFi® is expanding its co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in treatments such as BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM®Collection of Fillers, Natrelle® breast i
- Lilly's Olumiant Associated with Significant Hair Growth in Patients with Severe Alopecia Areatahttps://practicaldermatology.com/news/lillys-olumiant-associated-with-significant-hair-growth-in-patients-with-severe-alopecia-areata/2461144/Olumiant® (baricitinib) from Eli Lilly and company produced significant scalp, eyelash, and eyebrow hair regrowth at 52 weeks, with nearly 75% of those who responded to Olumiant 4mg achieving 90% scalp coverage. The 52-week pooled findings were presented at the
- Boehringer Ingelheim’s Effisayil Offers Sustained Relief from GPP Flareshttps://practicaldermatology.com/news/boehringer-ingelheims-effisayil-offers-sustained-releif-from-gpp-flares/2461143/Effisayil (Spesolimab) clears skin pustules in patients with generalized pustular psoriasis (GPP) flares within the first week after treatment, and these benefits are sustained over 12 weeks, according to data presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Bost
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Studyhttps://practicaldermatology.com/news/opzelura-shows-benefit-in-52-week-phase-3-vitiligo-study/2461139/New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura™) in adolescent and adult patients with nonsegmental vitiligo show that twice daily application was
- Dupixent Performs Well in Phase 3s for Prurigo Nodularishttps://practicaldermatology.com/news/dupixent-performs-well-in-phase-3s-for-prurigo-nodularis/2461138/Detailed positive results from the Phase 3 PRIME2 trial show Dupixent® (dupilumab) significantly reduced itch and skin lesions compared to placebo in adults with uncontrolled prurigo nodularis. Findings were presented in a late-breaking session at the American Academy of Dermat
- Compulink Partners with Promptly for New Suite of Serviceshttps://practicaldermatology.com/news/compulink-partners-with-promptly-for-new-suite-of-services/2461127/Compulink Healthcare Solutions has partnered with Promptly to launch Advantage Patient Experience™, a suite of easy-to-use features intended to provide patients with the latest in mobile device convenience, while simultaneously reducing the administrative burden on office staff.
- DERMWIRE Exclusive: FDA Clears Cutera’s AviClear Acne Devicehttps://practicaldermatology.com/news/dermwire-exclusive-fda-clears-cuteras-aviclear-acne-device/2461124/The U.S. Food and Drug Administration has cleared granted 510(k) clearance to Cutera’s AviClear acne device. This is the first energy device to receive a nod for the treatment of mild, moderate, and severe acne. AviClear targets acne at the source by selec
- Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results for KB301https://practicaldermatology.com/news/jeune-aesthetics-announces-positive-clinical-phase-1-efficacy-results-for-kb301/2461119/Aesthetics, Inc.’s KB301 demonstrated promise in proof-of-concept in the Phase 1 PEARL-1 study. Specifically, Cohort 2 of this trial evaluated KB301 for the improvement of fine lines and skin texture in the lower and upper cheek, and for improvement in skin thickness in
- Dove, Crown Coalition Applaud U.S. House of Representatives for Passing Crown Acthttps://practicaldermatology.com/news/dove-crown-coalition-applaud-us-house-of-representatives-for-passing-crown-act/2461116/The CROWN Coalition, a national alliance founded by Dove, National Urban League, Western Center on Law & Poverty and Color of Change, along with more than 90 members of the CROWN Coalition praise the U.S. House of Representatives for passing the CROWN A